|
THURSDAY, DECEMBER 8, 2022 |
| All times are CENTRAL Time
|
|
|
| |
|
|
| 7:00 am - 8:15 am CT |
POSTER SESSION 4 - Hall 1 |
|
| 7:00 am - 8:15 am CT |
SPOTLIGHT POSTER DISCUSSION SESSION #10 - Stars at Night Ballroom 3&4
Endocrine Therapy and Resistance
Chair: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX
Biomarkers of response and resistance
Luca Malorni, MD, PhD
Hospital of Prato, AUSL Toscana Centro
Prato, Italy
Mechanisms of resistance and new treatment strategies
Deepali Sachdev, PhD
University of Minnesota
Minneapolis, MN
|
|
| 7:00 am - 8:15 am CT |
SPOTLIGHT POSTER DISCUSSION SESSION #11 - Stars at Night Ballroom 1&2
Improving Outcome for TNBC: New Directions in Immunotherapy
Chair: Hope S. Rugo, MD
University of California San Francisco
San Francisco, CA
Enhancing
the Immune Response in HER2 Negative Breast Cancer
Heather McArthur, MD, MPH
UT Southwestern
Dallas, TX
Immunotherapy
Combinations and Correlative Markers
Rebecca Dent, MD
National Cancer Centre
Singapore, Singapore
Enhancing
the Effects of Immunotherapy in Metastatic Breast Cancer
Margaret Gatti-Mays, MD
The Ohio State University Comprehensive Cancer Center
Columbus, OH
|
|
| 7:00 am - 8:15 am CT |
SPOTLIGHT POSTER DISCUSSION SESSION #12 - Hemisfair Ballroom 1&2
Obesity and Breast Cancer
Chair: Tarah J. Ballinger, MD
Indiana University School of Medicine
Indianapolis, IN
Neil M. Iyengar, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Jennifer A. Ligibel, MD
Dana-Farber Cancer Institute
Boston, MA
Stephanie Walker, BSN, Advocate
Metastatic Breast Cancer Alliance
Tarboro, NC
|
|
| 8:30 am - 11:00 am CT |
GENERAL SESSION #3 - Hall 3
Moderators:
Carey K. Anders, MD
Duke University
Durham, NC
and
William M. Sikov, MD
Women & Infants Hospital
Providence, RI |
|
| 8:30 am - 8:45 am CT |
GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
Bardia A, Bidard FC, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon P, Babu S, Waters S, Deleu I, García-Sáenz J, Bria E, Cazzaniga M, Aftimos P, Cortés J, Scartoni S, Sahmoud T, Habboubi N, Grzegorzewski KJ, Kaklamani V. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; Institut Curie, Paris and Saint Cloud, France; Universitaire Ziekenhuizen (UZ) - Leuven Cancer Institute, Leuven, Belgium; Centro Médico Austral, Buenos Aires, Argentina; University Hospitals Seidman Cancer Center- Case Western Reserve University, Cleveland, OH, USA; Centre Hospitalier de l'Ardenne - Site de Libramont, Libramont-Chevigny, Belgium; Centre Jean Perrin, Clermont-Ferrand, France; Yonsei Cancer Center, Yonsei University Health System -Medical Oncology, Seoul, Republic of Korea; Universite catholique de Louvain, CHU UCL Namur—Site Sainte-Elisabeth, Namur, Belgium; Inova Schar Cancer Institute, Fairfax, Virginia; Moffit Cancer Center & Research Institute, Tampa, FL, USA; Bács-Kiskun Megyei Kórház, Kecskemét, Hungary; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; University of Virginia Cancer Center, Charlottesville, VA, USA; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN; Velindre Cancer Centre, Cardiff, UK; AZ Nikolaas, Sint-Niklaas, Belgium; Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Spain; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; Ospedale San Gerardo-ASST Monza, Monza, Italy; Institut Jules Bordet – Université Libre de Bruxelles, Brussels, Belgium; International Breast Cancer Center (IBCC), Quiron Group, Barcelona Spain; Menarini Group, Florence, Italy; Stemline Therapeutics/Menarini Group, New York, NY, USA; University of Texas Health Sciences Center, San Antonio, TX. |
|
| 8:45 am - 9:00 am CT |
GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial
Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, Hotko Y, Melkadze T, Nemsadze G, Neven P, Semegen Y, Vladimirov V, Zamagni C, Denys H, Forget F, Horvath Z, Nesterova A, Bennett M, Kirova B, Klinowska T, Lindemann JPO, Lissa D, Mathewson A, Morrow CJ, Traugottova Z, van Zyl R, Arkania E. Medical Oncology Department, Vall d’Hebron University Hospital and Breast Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Medical Center Verum, Kyiv, Ukraine; The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; Makiivka City Hospital of Donetsk Region, Makiivka; AV Medical Group, St Petersburg, Russian Federation; Central City Hospital, Uzhgorod National University, Uzhgorod, Ukraine; Oncology and Hematology Department, Academician Fridon Todua Medical Center - Research Institute of Clinical Medicine Tbilisi, Georgia; The Institute of Clinical Oncology, Tbilisi, Georgia; Multidisciplinary Breast Center, University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium; Bukovynsky Clinical Oncology Center, Chernivtsi, Ukraine; Pyatigorsky Oncology Dispensary, Pyatigorsk, Russia; Addarii Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical Oncology, Ghent University Hospital, Belgium; Centre Hospitalier de l'Ardenne-Site de Libramont, Libramont-Chevigny, Belgium; Center of Oncoradiology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary; Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan, Russian Federation; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK; Oncology Patient Safety, Oncology R&D, AstraZeneca, Cambridge, UK; Late Development, Oncology R&D, AstraZeneca, Cambridge, UK; Parexel International, Prague, Czech Republic; Parexel International, Bloemfontein, South Africa; Helsicore Israeli Georgian Medical Research Clinic, Tbilisi, Georgia.
|
|
| 9:00 am - 9:15 am CT |
GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study
Hurvitz SA, Schott AF (Presenter), Ma C, Hamilton E, Nanda R, Zahrah G, Hunter N, Tan AR, Telli ML, Anampa Mesias J, Jeselsohn R, Munster P, Lu H, Gedrich R, Mather C, Parameswaran J, Han HS. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Rogel Cancer Center, University of Michigan Health, Ann Arbor, MI; Washington University, St. Louis, MO; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA; University of Chicago, Chicago, IL, USA; Whittingham Cancer Center, Norwalk, CT, USA; Seattle Cancer Care Alliance, Seattle, WA; Levine Cancer Institute, Atrium Health, Charlotte, NC; Stanford University School of Medicine, Stanford, CA; Albert Einstein College of Medicine, Bronx, NY; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA; Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; University of California San Francisco, San Francisco, CA; Arvinas, Inc, New Haven, CT; H. Lee Moffitt Cancer Center, Tampa, FL, USA. |
|
| 9:15 am - 9:30 am CT |
GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial
Turner NC, Oliveira M, Howell S, Dalenc F, Cortés J, Gomez H, Hu X, Jhaveri K, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Toi M, Zhukova L, Yan C, Schiavon G, Foxley A, Rugo HS.
|
|
| 9:30 am - 9:45 am CT |
GS3-05 Discussant for GS3-01, GS3-02, GS3-03 and GS3-04
Fabrice André, MD, PhD
Gustave Roussy
Villejuif, France |
|
| 9:45 am - 10:00 am CT |
GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma CX, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Jolly T, Riley E, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block C, Ko N, Partridge AH, Chen WY, DeMeo MK, Attaya V, Okpoebo A, Liu Y, Gauthier E, Burstein H, Regan MM, Tolaney SM. Dana-Farber Cancer Institute, Boston, United States; Department of Biostatistics, Dana-Farber Cancer Institute; Miami Cancer Institute; Washington University School of Medicine; Abramson Cancer Center, University of Pennsylvania; Weill Cornell Medicine; Winship Cancer Institute, Atlanta, GA, USA; Indiana University School of Medicine; University of North Carolina Lineberger Comprehensive Cancer Center; University of Louisville Health - Brown Cancer Center; Aurora Health Care; University of Kansas Medical Center Westwood, Westwood, KS, USA; Vanderbilt-Ingram Cancer Center; Dana-Farber Cancer Institute, Boston, MA, USA; Boston Medical Center; Pfizer Inc; International Breast Cancer Study Group Statistical Center, Department of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. |
|
| 10:00 am - 10:15 am CT |
GS3-07 Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer
Guarducci C, Cristea S, Feit A, Naumenko S, Nardone A, Ma W, Russo D, Cohen Feit G, Feiglin A, Hermida-Prado F, Sherman S, Brown M, Michor F, Jeselsohn R. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biostatistics, Harvard Chan School of Public Health, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Biostatistics, Harvard Chan School of Public Health, Boston, MA, USA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biomedical Informatics, Harvard Medical School, Boston, MA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biomedical Informatics, Harvard Medical School, Boston, MA; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA;Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. |
|
| 10:15 am - 10:30 am CT |
GS3-08 Discussant for GS3-06 and GS3-07
Shom Goel, MBBS, B Med Sci (Hons)
Peter MacCallum Cancer Centre
Melbourne, Australia
|
|
| 10:30 am - 10:45 am CT |
GS3-09 Circulating Tumor Cells-driven choice of first line therapy for ER+ HER2- metastatic breast cancer: overall survival analysis of the randomized STIC CTC trial
Bidard F-C, Kiavue N, Alix-Panabières C, Dureau S, Bachelot T, Bourgeois H, Gonçalves A, Brain E, Ladoire S, Dalenc F, Gligorov J, Teixeira L, Emile G, Ferrero J-M, Loiraat D, Cabel L, Diéras V, Berger F, Jacot W, Pierga J-Y. Institut Curie; Montpellier University Hospital; Centre Léon Bérard; Clinique Victor Hugo; Institut Paoli-Calmettes; European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Centre Georges François Leclerc; Institut Claudius Régaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France; Institut Universitaire de Cancérologie AP-HP Sorbonne Université; APHP Hôpital Saint Louis; Centre François Baclesse; Centre Antoine Laccassagne; Institut Curie, Medical Oncology Department and D3i, Paris, France; Eugene Marquis Centre, Rennes, France; Institut du Cancer de Montpellier, Université de Montpellier, INSERM U1194, Paris, France; Institut Curie & Université Paris Cité. |
|
| 10:45 am - 11:00 am CT |
GS3-10 Discussant for GS3-09
Daniel Hayes, MD
University of Michigan
Ann Arbor, MI |
|
| 10:00 am - 5:00 pm CT |
EXHIBITS - Hall 2 |
|
| 11:00 am - 12:00 pm CT |
DEBATE - Hall 3
Are All CDK4/6 Inhibitors the Same or Different?
Moderator: Sung-Bae Kim, MD, PhD
University of Ulsan College of Medicine
Seoul, South Korea
PRO
Debra Patt, MD, MBA
Texas Oncology
Austin, TX
CON
Ruth O'Regan, MD
University of Rochester Medical Center
Rochester, NY
|
|
| 12:00 pm - 12:30 pm CT |
PLENARY LECTURE #2 - Hall 3
Moderator:Carlos Arteaga, MD
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
Premenopausal ER+ Breast Cancer: Past, Present, and Future
Prudence Francis, MD
Peter MacCallum Cancer Centre
Victoria, Australia |
|
| 12:30 pm - 1:00 pm CT |
BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN BASIC SCIENCE
Moderator: Jennifer Pietenpol, PhD
Vanderbilt University Medical Center
Nashville, TX
Guardian at the Gates: Genome Stability, Cell State, Plasticity, and Breast Cancer
Geoffrey M. Wahl, PhD
Salk Institute for Biological Studies
La Jolla, CA |
|
| 1:00 pm - 2:00 pm CT |
MOLECULAR TUMOR BOARD - Stars at Night Ballroom 1&2
Moderator: Giuseppe Curigliano, MD, PhD
European Institute of Oncology
Milano, Italy
Panelist:
Philippe Bedard, MD
Princess Margaret Cancer Centre
Toronto, Canada
Amy L. Delson, AIA
University of California San Francisco
Atherton, CA
Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN
Sara Hurvitz, MD, FACP
University of California San Francisco
Los Angeles, CA
Antonio Marra, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Aleix Prat, MD, PhD
Hospital Clínic Barcelona
Barcelona, Spain
Daniel Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH
|
|
| 1:00 pm - 2:00 pm CT |
FORUM #3 Stars at Night Ballroom 3&4
Modifying Tumor Response: Microbiome, Diet, and Fasting
Moderator: Sangeetha Reddy, MD, MSc
UT Southwestern Medical Center
Dallas, TX
Fungal regulation of breast tumor radiation response
Stephen L. Shiao, MD, PhD
Cedars-Sinai
Los Angeles, CA
Fasting and microbiotic
Guido Kroemer, MD, PhD, PU-PH
University of Paris Descartes
Paris, France
Microbiome and response to immunotherapy
Jennifer A. Wargo, MD
UT MD Anderson Cancer Center
Houston, TX
|
|
| 2:00 pm - 3:00 pm CT |
TRANSLATIONAL CONTROVERSIES - Stars at Night Ballroom 1&2
Moderator: Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center
New York, NY
RIP MTD
Hope S. Rugo, MD, FASCO
University of California San Francisco
San Francisco, CA
Geoffrey Shapiro, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
Randomized trials vs real world evidence
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA
Sean Khozin, MD, MPH
CancerLinQ, LLC
New York, NY
Ki 67
Nadia Harbeck, MD, PhD
University of Munich
Munich, Germany
Torsten Nielsen, MD, PhD, FRCPC
University of British Columbia
Vancouver, Canada
|
|
| 2:00 pm - 3:00 pm CT |
FORUM #4 - Stars at Night Ballroom 3&4
Demystifying CDKs in Breast Cancer: Beyond CDK4/6
Moderator: Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA
CDK4/6 inhibitor resistance: Biological mechanisms and novel approaches
Ariella Hanker, PhD
UT Southwestern Medical Center
Dallas, TX
Current status of CDK2 inhibitors in (pre-)clinical development
Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Inhibiting transcriptional CDKs in breast cancer
Raoul Charles Coombes, FRCP, PhD, MD, FMedSci
Imperial College
London, United Kingdom
|
|
| 3:00 pm - 5:00 pm CT |
EDUCATIONAL SESSION BLOCK #3
EDUCATIONAL SESSION BLOCK #3A - Hemisfair Ballroom 1&2
Management of Hereditary Risk: Moderate-Risk Genes and New Approaches
Moderator: Seema A. Khan, MD
Northwestern University
Chicago, IL
Cancer risks in patients with moderate penetrance gene mutations
Payal D. Shah, MD
Penn Medicine
Philadelphia, PA
Screening for high-risk patients: Does everyone need annual MRI with mammogram?
Madeleine M.A. Tilanus-Linthorst, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands
Hormonal exposure and risk in BRCA1/2 carriers
Joanne Kotsopoulos, MSc, PhD
University of Toronto
Toronto, Canada
EDUCATIONAL SESSION BLOCK #3B - Stars at Night Ballroom 1&2
Challenging Types of Breast Cancer
Moderator: Bora Lim, MD
Baylor College of Medicine
Houston, TX
Pathologic aspects
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Metaplastic breast cancer
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC
Inflammatory breast cancer
Filipa Lynce, MD
Dana-Farber Cancer Institute
Boston, MA
Lobular/pleomorphic breast cancer
Sibylle Loibl, MD, PhD
German Breast Group
Neu-isenburg, Germany
EDUCATIONAL SESSION BLOCK #3C - Stars at Night Ballroom 3&4
What ctDNA Can Tell Us
Moderator: Nicholas Turner, PhD, FRCP
The Royal Marsden Hospital
London, United Kingdom
Which is the best technique
Heather Parsons, MD, MPH
Dana-Farber Cancer Institute; Harvard Medical School
Boston, MA
Can ctDNA substitute tissue testing
Ben O'Leary, MBBS, PhD
The Institute of Cancer Research
London, United Kingdom
Using ctDNA in detecting disease
Minetta C. Liu, MD
Natera
Austin, TX
|
|
| 5:00 pm - 6:15 pm CT |
POSTER SESSION #5 AND ONGOING TRIALS #3 - Hall 1 |
|
| 5:00 pm - 6:15 pm CT |
SPOTLIGHT POSTER DISCUSSION SESSION #13 - Stars at Night Ballroom 1&2
Therapeutic Approaches for HR+/Her2- Breast Cancer
Chair: Kevin Kalinsky, MD
Winship Cancer Institute at Emory University
Atlanta, GA
Pre-surgical and
Metastatic Oral SERD Trials
Rinath M. Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA
PI3K/AKT Pathway
Inhibition
Neil Vasan, MD, PhD
Columbia University
New York, NY
CDK 4/6 inhibitor and ADC Updates
Phillipe Bedard, MD
Princess Margaret Cancer Centre
Toronto, Canada
Roberta Albany, Advocate
Cancer in the Know
Mt Penn, PA
|
|
| 5:00 pm - 6:15 pm CT |
SPOTLIGHT POSTER DISCUSSION SESSION #14 - Stars at Night Ballroom 3&4
Breast Cancer Risk Modeling
Chair: Judith Balmaña, MD, PhD
Vall d'Hebron University Hospital
Barcelona, Spain
Genetics
Jennifer Caswell-Jin, MD
Stanford
Stanford, CA
Imaging
Sarah Eskreis-Winkler, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Judith Mayer, Advocate
Breast Cancer Straight Talk
San Francisco, CA
|
|
| 5:00 pm - 6:15 pm CT |
SPOTLIGHT POSTER DISCUSSION SESSION #15 - Hemisfair Ballroom 1&2
Local Regional/Management of the Axilla
Chair: Andrea V. Barrio, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY
Axillary management
Tracy-Ann Moo, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Local recurrence invasive cancer and DCIS
Jennifer K. Plichta, MD
Duke University School of Medicine
Durham, NC
Reconstruction, Topical Tam, MRI
Rachel Greenup, MD, MPH
Yale School of Medicine
New Haven, CT
|
|
|
OPEN SATELLITE EVENTS - Marriott Rivercenter |
|
| |
|
|
| 7:00 pm - 8:45 pm CT |
Molecular Imaging and Breast Cancer: Selecting and Evaluating Targeted Treatments presented by Society of Nuclear Medicine and Molecular Imaging
For more information and to register visit our website https://www.snmmi.org/sanantonio22
|
|
| 7:15 pm - 9:15 pm CT |
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer — An Independent Satellite Symposium Held in Conjunction with the 45th Annual San Antonio Breast Cancer Symposium presented by Research to Practice
San Antonio Marriott Rivercenter, Grand Ballroom G-M, Third Floor
For more information and to register visit our website http://www.researchtopractice.com/Meetings/SA2022
|
|
|